SV

Street Verdict

Analyst Scorecard

MEDANTA · NSE

Global Health Limited

₹1,480.2

+0.13% (+₹1.9)

Prev. close

₹1,478.3

Volume

2,65,365

Delivery %

47.3%

As of

20 Nov 2026

Price history

₹1,480.2+₹37.5 (+2.60%) · 3M
18 Aug 2026 → 20 Nov 2026
1,2001,2501,3001,3501,4001,4501,50018 Aug09 Sept06 Oct29 Oct20 Nov
Daily closes · updates after each session

Analyst sentiment

Analysts lean bullish

2 analyst stances · last 90 days · one per analyst

Trackable

2 · 2 bull / 0 neutral / 0 bear

Long-Horizon

none in range

Commentary

none in range

Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded

Bullish 100% (2)Neutral 0% (0)Bearish 0% (0)
Explore by date range →

Analyst opinions

CallAnalystInstrumentVerdictActions
Market commentary · 1 · levels, conditionals, previews, macro & hedged views — context, not graded
CallAnalystInstrumentVerdictActions

Fundamentals

About Global Health Limited

Global Health Limited, together with its subsidiaries, provides healthcare services in India. The company offers treatments in the areas of digestive and hepatobiliary sciences, cardiac and cancer care, neurosciences, gastrosciences, orthopaedics, renal care, liver transplant, lung transplant, bone marrow transplant, chest surgery, gynaecology and gynaeoncology, paediatric care, obstetrics, emergency, ENT, head and neck surgery, internal medicine, respiratory and sleep medicine, peripheral vascular and endovascular sciences, endocrinology and diabetes, rheumatology and immunology, radiology and imaging, ophthalmology, critical care, dermatology, dentistry, lab and pathology, and dietetics and nutrition, as well as plastic, aesthetic, and reconstructive surgery. It also provides second opinions, lab tests and diagnostics, homecare and elder care services, telemedicine and air ambulance services, and e-ICU services, and health plans checkup services. In addition, the company is involved in trading pharmacy and other medical consumables; and medical and healthcare education activities. The company operates a network of hospitals under the Medanta brand. Global Health Limited was incorporated in 2004 and is based in Gurugram, India.

Details

Sector

Healthcare

Industry

Medical Care Facilities

CEO

Mr. Pankaj Prakash Sahni

Headquarters

Gurugram

Employees

12,600

Key stats

Market cap

₹37,651.01 Cr

P/E ratio (TTM)

61.0

Dividend yield

0.04%

EPS (TTM)

₹22.98

Beta (1Y · daily vs NIFTY 50)

0.77

Beta (5Y · monthly vs NIFTY 50)

0.54

Shares float

8.85 Cr

EPS · quarter ended Jun 2026

₹5.90

Financial Performance

01 · Financials

0 Cr2000 Cr4000 Cr6000 Cr₹0%5%10%15%FY21FY22FY23FY24FY25FY26
RevenueNet incomeNet income ÷ revenue

EBITDA is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures. Net income ÷ revenue is not drawn for FY21 and FY22 (revenue was nil or not reported).

02 · Earnings Per Share (EPS)

05101520₹FY23FY24FY25FY26

03 · Dividend Profile

0001₹0%0%0.1%0.1%22 Aug 2514 Aug 26
Dividend (₹/share)Annualised yield

Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based

-50%0%50%100%FY21FY22FY23FY24FY25FY26
SalesFixed assetsTrade receivablesInventory

05 · Capital Structure & Asset Utilization

0 Cr2000 Cr4000 Cr6000 Cr₹0×0.25×0.5×0.75×1×FY21FY22FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

0 Cr2000 Cr4000 Cr6000 Cr₹FY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

-1000 Cr0 Cr1000 Cr2000 Cr₹FY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemFY21FY22FY23FY24FY25FY26
——₹2,694.25 Cr₹3,275.11 Cr₹3,692.32 Cr₹4,410.27 Cr
EBITDA
——₹677.12 Cr₹873.74 Cr₹906.26 Cr₹1,016.67 Cr
₹29.00 Cr₹196.00 Cr₹326.08 Cr₹478.19 Cr₹481.44 Cr₹556.46 Cr
Diluted EPS
——₹10.15₹17.8₹17.18₹18.42

Revenue, Total expenses (as filed), Employee benefit expense, Other expenses, EBITDA, Tax provision, Interest expense, Other income, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Net income for Mar 2023 could not be checked against the company's own annual report: this page shows ₹326.08 Cr while the annual report gives ₹263.25 Cr (19.3% apart).

EBITDA for Mar 2023 could not be checked against the company's own annual report: this page shows ₹677.12 Cr while the annual report gives ₹463.96 Cr (31.5% apart).

09 · Balance Sheet

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹2,694.00 Cr₹3,146.00 Cr₹4,097.00 Cr₹4,280.00 Cr₹4,766.00 Cr₹5,905.00 Cr
——₹1,121.95 Cr₹801.87 Cr₹717.73 Cr₹1,190.05 Cr
Stockholders' equity
₹1,383.00 Cr₹1,616.00 Cr₹2,429.00 Cr₹2,906.00 Cr₹3,387.00 Cr₹3,962.00 Cr

Current assets, Trade receivables, Cash & equivalents, Non-current assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹242.00 Cr₹311.00 Cr₹645.00 Cr₹612.00 Cr₹624.00 Cr₹714.00 Cr
Investing cash flow
——₹-342.34 Cr₹-440.80 Cr₹-720.94 Cr₹-1,089.11 Cr
——₹345.64 Cr₹-513.92 Cr₹-97.23 Cr₹271.85 Cr
Capital expenditure
₹-146.00 Cr₹-274.00 Cr₹-236.00 Cr₹-279.00 Cr₹-517.00 Cr₹-838.00 Cr
End cash position
——₹767.24 Cr₹424.61 Cr₹230.20 Cr₹127.33 Cr

Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Dividends paid, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source has no quarterly cash-flow-statement coverage.

11 · Shareholding Pattern

NSE, quarterly

Line itemNov 22–Mar 23(3Q)Jun 23Sep 23Dec 23Mar 24–Sep 24(3Q)Dec 24–Mar 25(2Q)Jun 25–Dec 25(3Q)Mar 26Jun 26
Promoter33.08%33.07%33.06%33.05%33.04%33.03%33.01%33.01%33.00%
Public66.92%66.93%66.94%66.95%66.96%66.97%66.93%66.92%66.91%
Employee trusts0.00%0.00%0.00%0.00%0.00%0.00%0.06%0.08%0.09%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.25 L Cr₹1,769.938.85.0913.7%0.06+11.9%+3.7%
Divi's Laboratories Limited₹2.66 L Cr₹10,037.590.815.8515.3%0.00+12.3%+47.5%
Torrent Pharmaceuticals Limited₹1.79 L Cr₹4,738.579.421.3125.8%1.79+21.5%+32.5%
Laurus Labs Limited₹1.27 L Cr₹2,34894.823.9416.8%0.48+22.0%+146.2%
Apollo Hospitals Enterprise Limited₹1.23 L Cr₹8,599.558.812.9520.5%0.90+15.7%+10.1%
Zydus Lifesciences Limited₹1.19 L Cr₹1,188.126.74.4018.6%0.46+18.4%+22.3%
Lenskart Solutions Limited₹1.16 L Cr₹689.7181.413.305.6%0.35+35.4%—
Dr. Reddy's Laboratories Limited₹1.14 L Cr₹1,37440.63.0211.4%0.21+3.2%+14.5%
Cipla Limited₹1.13 L Cr₹1,40238.93.2711.3%0.02+2.1%-6.7%
Mankind Pharma Limited₹1.03 L Cr₹2,47545.96.3111.7%0.39+17.0%+3.1%
Aurobindo Pharma Limited₹98,101.93 Cr₹1,70526.62.599.2%0.21+6.4%+48.4%
Global Health Limited₹34,911.78 Cr₹1,325.862.98.8114.0%0.30+18.7%+4.0%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

Documents

Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.

MEDANTA

UAE ranks joint first globally in personal safety, scores 96% in Gallup Global Safety Report

Gulf News · 2 days ago

MEDANTA

As Global Health Aid Dries Up, Non-Profit Drug Development Faces New Challenges

Global Health Limited faces a shrinking funding environment as donor governments cut global health budgets, with the Gates Foundation reducing PDP grants by nearly a quarter in 2024 and the UK’s support rising only modestly. This financial squeeze threatens the development pipeline of neglected‑disease medicines, as 12 product development partnerships report nearly 300 candidates in various trial stages. The uncertainty may force a “natural selection” of the most viable partnerships, potentially curtailing progress against malaria, tuberculosis and other tropical diseases.